



## LJMU Research Online

**Kroesen, SH, van Bakel, BMA, de Bruin, M, Pisters, MF, Ortega, FB, Hopman, MTE, Thijssen, DHJ, Bakker, EA and Eijsvogels, TMH**

**A remote booster program to attenuate sedentary behaviour in patients with coronary artery disease: A Randomized Controlled Trial**

<http://researchonline.ljmu.ac.uk/id/eprint/26070/>

### Article

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Kroesen, SH, van Bakel, BMA, de Bruin, M, Pisters, MF, Ortega, FB, Hopman, MTE, Thijssen, DHJ, Bakker, EA and Eijsvogels, TMH (2025) A remote booster program to attenuate sedentary behaviour in patients with coronary artery disease: A Randomized Controlled Trial. European Journal**

LJMU has developed [LJMU Research Online](http://researchonline.ljmu.ac.uk/) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact [researchonline@ljmu.ac.uk](mailto:researchonline@ljmu.ac.uk)

<http://researchonline.ljmu.ac.uk/>

1 **A remote booster program to attenuate sedentary behaviour in**  
2 **patients with coronary artery disease: A Randomized Controlled Trial**

3 Sophie H. Kroesen, PhD<sup>a</sup>; Bram M.A. van Bakel, MD, PhD<sup>a</sup>; Marijn de Bruin, PhD<sup>b</sup>; Martijn F. Pisters, PhD<sup>c,d,e</sup>;  
4 Francisco B. Ortega, PhD<sup>f,g,h</sup>; Maria T.E. Hopman, MD, PhD<sup>a</sup>; Dick H.J. Thijssen, PhD<sup>a,i</sup>; Esmée A. Bakker,  
5 PhD<sup>a,f,j</sup>; Thijs M.H. Eijssvogels, PhD<sup>a</sup>

6 **Affiliations:**

7 <sup>a</sup> Department of Medical BioSciences, Radboud university medical centre, Nijmegen, The Netherlands

8 <sup>b</sup> Department of IQ healthcare, Radboud university medical centre, Nijmegen, The Netherlands

9 <sup>c</sup> Department of Rehabilitation, Physical Therapy Science and Sport, University Medical Centre Utrecht Brain Centre,  
10 Utrecht University, Utrecht, The Netherlands

11 <sup>d</sup> Research Group Empowering Healthy Behaviour, Department of Health Innovations and Technology, Fontys  
12 University of Applied Sciences, Eindhoven, The Netherlands

13 <sup>e</sup> Centre for Physical Therapy Research and Innovation in Primary Care, Julius Health Care Centres, Utrecht, the  
14 Netherlands

15 <sup>f</sup> Department of Physical Education and Sports, Faculty of Sports Science, Sport and Health University Research  
16 Institute (iMUDS), University of Granada, Granada, Spain

17 <sup>g</sup> CIBEROBN Physiopathology of Obesity and Nutrition, Granada, Spain

18 <sup>h</sup> Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

19 <sup>i</sup> Research Institute for Sports and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom

20 <sup>j</sup> Department of Primary and Community Care, Radboud university medical centre, Nijmegen, The Netherlands

21

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](mailto:reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

1 **Running head:** A booster program to attenuate sedentary behaviour

2

3 **Previous presentations:** This work is not presented previously

4

5 **Source of support:** This study was supported by the Dutch Heart Foundation (senior E-Dekker grant  
6 #2017T051). EAB has received funding from the European Union's Horizon 2020 research and innovation  
7 program under the Marie Skłodowska-Curie grant agreement No [101064851].

8

9 **Disclaimers:** Not applicable

10

11 **Data availability statement:** Data from the SIT LESS Booster randomized controlled trial are available upon  
12 reasonable request via the corresponding author.

13

14 **Address for correspondence:**

15 T.M.H. Eijsvogels, PhD, Radboud university medical centre, Dept. of Medical BioSciences (route 928), P.O.  
16 Box 9101, 6500 HB, Nijmegen, The Netherlands. E-mail: [Thijs.Eijsvogels@radboudumc.nl](mailto:Thijs.Eijsvogels@radboudumc.nl), Telephone: (+31)  
17 (0)24 36 14273, Fax: (+31) (0)24 3668340

18

19

1 **Word count:**

2 **Word count abstract:** 249

3 **Total word count (Article incl. references/exc. references):** 4763 / 3364

4 **Number of tables:** 1

5 **Number of figures:** 4

6

7 **ABSTRACT**

8 **Aims:** Sedentary time (ST) can be reduced in patients with coronary artery disease (CAD) during cardiac  
9 rehabilitation (CR), but most patients relapse to sedentarism within months. We examined the  
10 effectiveness of a 3-week remote booster intervention on ST changes in CAD patients.

11 **Methods:** CAD patients who previously (2.0 [1.9 – 2.2] years) completed CR were included in this  
12 randomized controlled trial (1:1, stratified for gender). All participants received usual care, whereas  
13 booster participants additionally received a 3-week remote behavioral change intervention. The primary  
14 outcome was the change in accelerometer-derived ST from baseline to post-intervention and secondary  
15 outcomes included changes in sedentary behaviour and physical activity (PA) characteristics. A baseline  
16 constrained linear mixed-model on an intention-to-treat basis was used.

17 **Results:** Participants (19% female, booster: n=21, control: n=21) were 69 [63-75] years old. Greater  
18 decreases in ST (-1.3 (95% confidence interval (CI): -2.0; -0.6) *versus* -0.1 (95% CI: -0.8; 0.6) h/day,  $p_{\text{interaction}}=0.012$ ) and number of prolonged sedentary bouts (-1.1 (95% CI: -1.6; -0.6) *versus* 0.2 (95% CI: -0.3;  
19 0.7) bouts/day,  $p_{\text{interaction}}<0.001$ ) in combination with larger increases in light PA (+1.1 (95% CI: +0.5; +1.8)  
20 *versus* +0.2 (95% CI: -0.4; +0.8) h/day,  $p_{\text{interaction}}=0.030$ ) were found for the booster *versus* control group.

1 Changes in moderate-to-vigorous PA ( $p_{\text{-interaction}}=0.13$ ) and step count ( $p_{\text{-interaction}}=0.18$ ) did not differ  
2 between groups.

3 **Conclusion:** The remote booster program effectively reduced ST and increased light PA in CAD patients.  
4 These findings highlight the potential to change physical (in)activity behaviour of patients beyond  
5 completion of traditional CR programs.

6 **Trial registration:** NCT06038188 (Clinical Trials.gov)

7  
8 **KEYWORDS:** Cardiac rehabilitation; e-Health; prevention; sitting; physical activity; cardiovascular disease.

## 10 LAY SUMMARY

11 This study assessed the effectiveness of a remote 3-week booster program on reductions in daily sitting  
12 time in patients with coronary artery disease who previously completed a cardiac rehabilitation program.

- 13 • The booster program successfully reduced sitting time (-1.3 hrs/day) and increased light intensity  
14 physical activity (+1.1 hrs/day).
- 15 • A remote booster program is a novel and promising strategy to support patients with coronary  
16 artery disease to achieve a physically active lifestyle beyond cardiac rehabilitation.

## 18 INTRODUCTION

19 Patients with coronary artery disease (CAD) spend substantially more time sedentary per day compared  
20 to the general population (10.4 *versus* 9.4 h/day)<sup>1,2</sup>. A high sedentary time (ST, i.e.  $\geq 9.5$  h/day) is associated  
21 with an increased risk of cardiovascular disease morbidity and mortality, even after accounting for

1 traditional risk factors<sup>3</sup>. The interruption and replacement of ST with light or moderate-to-vigorous  
2 intensity physical activity (LIPA or MVPA) can improve cardiovascular risk factors<sup>4</sup> and attenuates the risk  
3 for adverse health outcomes<sup>1,5</sup>. Contemporary exercise-based cardiac rehabilitation (CR) programs aim to  
4 enhance habitual physical activity (PA) of CAD patients, but do not specifically target ST<sup>6</sup>. As a result, CR  
5 graduates demonstrated no or only slight reductions in ST (-0.4--0.2 h/day) and no changes in the number  
6 of prolonged sedentary bouts<sup>2,7,8</sup>.

7 We previously showed that enrichment of CR with a tailored sedentary behaviour intervention (SIT  
8 LESS) induces greater reductions in some ST indicators compared to usual care. However, these beneficial  
9 behavioral changes were only temporary as attainment of sustainable PA habits after CR remain  
10 challenging<sup>9</sup>. eHealth-based programs may offer potential strategies for individual patients to maintain  
11 beneficial PA levels following CR<sup>9</sup>. Moreover, remote booster programs may already nudge CR graduates  
12 towards a more physically active lifestyle<sup>10</sup>. Such booster programs should ideally include continued  
13 support to allow self-monitoring of behaviour, goal-setting and associated feedback<sup>9</sup>. However, the effect  
14 of a remote eHealth-based booster program aiming to reduce ST in patients with CAD who followed a ST  
15 reduction program previously is currently unknown.

16 Our randomized controlled trial examined the effectiveness of a remote 3-week booster behaviour  
17 intervention program on changes in objectively measured ST. Secondary outcomes included the  
18 participation rate to the study, changes in other characteristics of sedentary behaviour (i.e. prevalence of  
19 prolonged sedentary bouts  $\geq 30$  min, proportion of patients with ST  $\geq 9.5$  h/day), LIPA, MVPA, and step  
20 count. We hypothesized that the booster intervention would result in a lower ST and increased PA  
21 compared to control.

22

23

## 1 METHODS

### 2 Study design and population

3 A parallel-group randomized controlled trial was conducted to determine the effectiveness of a booster  
4 intervention on reducing ST. The booster program consisted of a 3-week, fully-remote and personalized  
5 behaviour change intervention with a primary focus on reducing and interrupting ST in patients with CAD  
6 (i.e. myocardial infarction or (stable) angina pectoris) (Clinical Trials.gov NCT06038188). The booster is a  
7 compressed version of the 'Sedentary Behaviour Intervention as a Personalized Secondary Prevention  
8 Strategy' (SIT LESS) intervention, which has previously been described in detail<sup>11</sup> and the protocol can be  
9 found in **Supplementary File 1**. Participants who completed the original SIT LESS intervention (n=97)  
10 during their CR program (1.5 to 2.5 years ago) were screened for this study. First, participants were  
11 excluded if they refused to be contacted for follow-up studies or if accelerometer data was repeatedly  
12 unavailable (e.g. refused accelerometer measurements or no show) during the original SIT LESS RCT.  
13 Thereafter, electronic patient files were screened, and participants were excluded when they were  
14 deceased or had medical conditions that made it physically unable to stand or walk. Eligible participants  
15 were accordingly approached for participation in this study by email and phone contact including  
16 reminders in August 2023 by a researcher of the study team (S.K.). After inclusion, baseline characteristics  
17 were collected including baseline assessment of ST and PA characteristics by an accelerometer  
18 (**Supplementary Figure 1**). Following baseline measurements, participants were randomly assigned into  
19 the control or booster group. The control group received usual care, which included cardiovascular risk  
20 management and regular cardiology consultation. The booster group additionally received the booster  
21 intervention. Finally, the accelerometry measurement was repeated in both groups at the end of the  
22 booster intervention (post-intervention, ~1 month post-baseline measurement). There were no changes  
23 to the study protocol after trial commencement. Our trial was approved by the Medical Ethics Committee

1 of the Radboud university medical centre (NL72604.091.20), and all participants gave written informed  
2 consent. The CONSORT checklist is available in **Supplementary Table 1**<sup>12</sup>.

#### 4 **Randomization and masking**

5 Participants were randomly allocated (1:1) to the control or booster group using the validated variable  
6 block randomization algorithm of Castor CDMS software (Castor Electronic Data Capture 2021, Ciwit B.V.,  
7 Amsterdam, The Netherlands). Random block sizes ranging from two to six participants were applied,  
8 while stratification by gender was used to ensure balance of the treatment arms. Allocation concealment  
9 was ensured as randomization by the centralized method (Castor CDMS) was released after all the baseline  
10 measurements were completed. Due to the nature of the intervention, the research team and participants  
11 were not blinded to the treatment assignment. However, the primary outcome assessment was performed  
12 blinded using an automatized data processing script based on a unique participant identification number,  
13 independent from the randomization procedure.

#### 15 **Booster intervention**

16 Participants in the booster group received a completely remote version of the SIT LESS intervention<sup>11</sup>. SIT  
17 LESS was developed in close collaboration with patients and nurse specialists following the intervention  
18 mapping adaptation framework<sup>13</sup> as described elsewhere<sup>11,14</sup>. The booster intervention consisted of a 3-  
19 week, personalized behaviour change intervention. At the start of the booster program (week 1),  
20 participants received one remote consultation (30 min by video or telephone, **Supplementary Figure 1**)  
21 consisting of an educational refresher, personal goal-setting and motivational interviewing with coping  
22 planning to reduce ST. Participants also received a pocket-worn activity tracker by mail, which was



1 connected to a smartphone application (RISE, Appbakkers B.V., Zwolle, The Netherlands). The activity  
2 tracker provided vibrotactile feedback after a predefined limit for sedentary bouts was exceeded (i.e. 30  
3 min) and the smartphone application enabled participants and researchers to register and adjust personal  
4 goals and review daily ST<sup>15</sup>. Participants were contacted twice by telephone ( $\pm 10$  min per contact) in week  
5 2 and 3, with the aim to resolve practical issues (e.g. activity tracker, smartphone application), evaluate  
6 the personal ST goal and define an action plan to (further) reduce ST the upcoming week using  
7 motivational interviewing techniques to stimulate the participant. The intervention was delivered by a  
8 researcher of the study team (S.K.), who followed a comprehensive training course in delivering the  
9 intervention consultations and applying motivational interviewing, under the guidance of a behavioral  
10 psychologist. The SIT LESS manual was followed for the consultation and a standard operating procedure  
11 was used for the telephone coaching, both are described elsewhere<sup>11</sup>.

### 13 **Outcomes**

14 The pre-specified primary outcome was the change in objectively measured ST, expressed in h/day, from  
15 baseline to directly post-intervention (**Supplementary Figure 1**)<sup>11</sup>. Secondary outcomes included  
16 participation rate, changes in the number of prolonged sedentary bouts ( $\geq 30$  minutes), prevalence of ST  
17  $\geq 9.5$  h/day, time spent in LIPA and MVPA, and daily step count.

### 19 **Measurements**

20 ST and PA were objectively assessed using a validated accelerometer (ActivPAL3<sup>TM</sup>micro, PAL Technologies  
21 Ltd., Glasgow, United Kingdom)<sup>16</sup>. The ActivPAL is a small device (25x45x5 mm), waterproof attached to  
22 the participant's thigh using hypoallergenic tape. The ActivPAL combines a tri-axial accelerometer with an

1 inclinometer which accurately distinguishes between sitting, standing and walking<sup>16</sup>. Participants were  
2 instructed to wear the ActivPAL24 h/day for 8 consecutive days and to fill in a diary with sleep times and  
3 moment of attachment and detachment. Raw data were analysed by a modified version of the script of  
4 Winkler et al.<sup>17</sup>. Total ST (Metabolic Equivalent of Task score (METs)  $\leq 1.5$  while awake in a sitting, lying or  
5 reclining posture)<sup>18</sup> was expressed in h/day and accumulation of ST was examined by calculating the  
6 number of prolonged ( $\geq 30$  min) sedentary bouts. The daily ST was dichotomized using 9.5 h/day as cut-off  
7 as it was previously shown that exceeding this upper limit of normal was associated with an increased risk  
8 of morbidity and mortality<sup>3</sup>. PA was categorized as LIPA (METs  $< 3$ ) or MVPA (METs  $\geq 3$ ) and expressed in  
9 h/day, whereas step count was expressed as the number of steps/day. Accelerometry data were gathered  
10 at baseline and post-intervention.

11 Baseline characteristics were derived from the hospital electronic patient files and a telephone  
12 interview. Subsequently, the Charlson Comorbidity index was calculated<sup>19</sup>. For participants randomized to  
13 the booster-arm, the adherence was assessed by counting the number of valid wear days of the activity  
14 tracker ( $\geq 10$  h/day), and by dividing the number of valid days by the total number of days of the  
15 intervention period x 100%. The number of completed remote consultations and telephone consultations  
16 was noted.

17  
18 **Sample size**  
19 As our study has an explorative character, no formal sample size calculation was performed a priori to trial  
20 initialization<sup>11</sup>. In the original SIT LESS study, the Cohen's D effect size for the primary outcome sedentary  
21 time was 0.3<sup>20</sup> with an alpha of 0.05 and beta of 0.2 (power 0.8). According to G\*power (version 3.1.)<sup>21</sup>,  
22 the (a posteriori) estimated sample size needed for this study was 24 participants (12 in each study arm)

1 based on previously mentioned parameters, see also **Supplemental file 1**. Given the secondary outcome  
2 to assess the participation rate to the booster study, all eligible participants were approached.

3

#### 4 **Statistical analyses**

5 All statistical tests were performed using R version 4.2.1 with packages “lme4”, “lmmstar”, “emmeans”,  
6 “compositions”, and “Hotelling”. All tests were two-sided, confidence intervals (CI) were at the 95% level  
7 and P-values <0.05 were considered statistically significant. Continuous normally distributed data were  
8 presented as mean ± standard deviation (SD), continuous not-normally distributed data as median  
9 [interquartile range] (IQR) and categorial variables as frequency (%). All data were visually inspected for  
10 normality and the Bartlett test was used to assess homoscedasticity.

11 Primary and secondary outcome analysis were performed on an intention-to-treat basis using a  
12 constrained (i.e. baseline adjusted) linear mixed-model analysis to handle missing data and to avoid  
13 baseline imbalances between treatment arms<sup>22</sup>. Time (categorical) and time\*group were included in the  
14 model. In addition, we evaluated the difference between the control and booster group in the proportion  
15 of participants with ST ≥9.5 h/day post-intervention by constrained logistic mixed model analysis.  
16 Assumptions of normality of residuals, and homoscedasticity were checked for all models. Additionally,  
17 we performed a compositional data analysis (CoDA) to explore the change in the daily distribution of the  
18 movement behaviours induced by the booster program. Time spent in sleep, ST, LIPA and MVPA was first  
19 normalized to 24 h/day. Compositional means were computed for the proportion of time spent in the  
20 different settings at baseline and post-intervention. The change in composition as a proportional change  
21 from the baseline overall composition was determined and compared between groups using the Hotelling  
22 T<sup>2</sup> test for multivariate pairwise comparisons<sup>23,24</sup>.

1 To assess the presence of potential selection bias among study participants, historical sedentary  
2 behaviour and PA characteristics were compared between our analytical cohort (participants of the  
3 Booster trial) and non-participants (participants of the SIT LESS trial not participating in the Booster trial)  
4 using an independent samples t-test (continuous normally distributed data with homogeneity of variance),  
5 Wilcoxon-signed rank test (continuous not-normally distributed data or no homogeneity of variance) or  $\chi^2$   
6 test (categorical data). Mixed-model analysis with baseline measurement as reference were used to assess  
7 the effect of time in the analytical cohort.

## 8 RESULTS

### 9 Participant characteristics

10 The participation rate to the Booster trial was 55% (48 included participants out of 87 eligible  
11 participants)(**Figure 1**). The baseline measurement were performed in 42 participants between 30 August  
12 2023 and 11 November 2023, which was 2.0 [1.9 – 2.2] years after CR enrolment. Participants were 69 [63-  
13 75] years old and 8 (19%) were female (**Table 1**). Our analytical cohort did not differ in historical sedentary  
14 behaviour and PA characteristics from the non-participants (**Supplementary Table 2, Supplementary**  
15 **Figure 2 and Supplementary Figure 3**).

16 Participants were randomly assigned to the booster group (n=21) and control group (n=21) (**Table**  
17 **1**). Post-intervention measurements were performed at 35 [35-36] days after baseline measurements  
18 between 11 October 2023 and 13 December 2023. Two participants (5%) dropped out in the booster group  
19 during the intervention period (**Figure 1**). The adherence to the daily use of the activity tracker was 79 [67-  
20 91] % (**Supplementary Table 3**). No study-related adverse events occurred.

### 22 Sedentary behaviour

23 Greater baseline to post-intervention decreases in ST were found in the booster *versus* control group (-1.3  
24 (95% CI -2.0; -0.6) *versus* -0.1 (95% CI -0.8; 0.6) h/day,  $p_{\text{interaction}}=0.012$ , **Figure 2A, Supplementary Table 4**,

1 **Supplementary File 2**). Furthermore, greater reductions in the daily number of prolonged sedentary bouts  
2 were observed in the booster *versus* control group (-1.1 (95% CI -1.6; -0.6) *versus* 0.2 (95% CI -0.3; 0.7)  
3 bouts/day,  $p_{\text{-interaction}} < 0.001$ , **Figure 2B, Supplementary File 2**). The post-intervention prevalence of ST  $\geq 9.5$   
4 h/day was, however, not significantly different between the booster and control group (26% *versus* 52%,  
5  $p = 0.11$ ) (**Supplementary Table 4, Supplementary File 2**).

6  
7 **Physical activity**  
8 Larger baseline to post-intervention increases in LIPA were found for the booster *versus* control group  
9 (+1.1 (95% CI: +0.5; +1.8) *versus* +0.2 (95% CI: -0.4; +0.8) h/day,  $p_{\text{-interaction}} = 0.030$ ), **Figure 3A,**  
10 **Supplementary File 2**). Changes in MVPA (-0.0 (95% CI: -0.1; +0.1) *versus* -0.2 (95% CI: -0.3; -0.0) h/day,  $p_{\text{-interaction}} = 0.13$ , **Figure 3B, Supplementary File 2**) and step count did not differ between groups (-121 (95%  
11 CI: -1,137; +894) *versus* -1,053 (95% CI: -2,039; -68) steps/day,  $p_{\text{-interaction}} = 0.18$ , **Figure 3C, Supplementary**  
12 **File 2**).

### 15 **Compositional data analysis**

16 The compositional data analysis showed that the booster group reduced ST by 18% and increased LIPA by  
17 17% compared to baseline, while MVPA (-1% from baseline) and sleep (-1%) did not change (**Figure 4**). In  
18 the control group, both the proportion of time spent in ST (3%) and LIPA (9%) increased from baseline,  
19 while the proportion of time spent in MVPA (-10%) and sleep (-2%) reduced from baseline. The group\*time  
20 interaction did not reach significance ( $p = 0.16$ ) (**Figure 4**).

21  
22  
23

## 1 **DISCUSSION**

2 This randomized controlled trial examined the effects a remote 3-week booster intervention in patients  
3 with CAD who completed CR combined with a ST reduction program 1.5 to 2.5 years ago. We found that  
4 the booster induced a greater reduction in ST and in the number of prolonged sedentary bouts, and a  
5 larger increase in LIPA compared to the control group in the short-term. These collective findings show  
6 that a short and remote booster program can effectively reduce sedentary behaviour while increasing  
7 LIPA. Therefore, this booster program offers a novel possibility to support patients with CAD to achieve  
8 sustainable lifestyle changes beyond CR-completion, which is hallmark of tertiary prevention.

### 9 10 **Sedentary behaviour and physical activity**

11 In line with our hypothesis, this remote eHealth-based booster program led to a reduction of ST and  
12 increase of LIPA by more than one hour and lowered the number of prolonged sedentary bouts. The  
13 changes are larger than observed in the original hybrid, 12-week SIT LESS study (ST: -0.5 h/day, LIPA: +0.4  
14 h/day) in patients with CAD<sup>20</sup>. A meta-analysis in the general population showed that objectively measured  
15 ST reduced by 35 min/day following eHealth interventions targeting sedentary time<sup>25</sup>, where a Cochrane  
16 review in community dwelling older adults showed no effects of sedentary behaviour reduction  
17 programs<sup>23</sup>. Our outcomes are likely to be clinically relevant as the replacement of one hour of ST with  
18 standing and/or LIPA improves cardiorespiratory risk factors<sup>26</sup> and reduces the risk of all-cause mortality<sup>5</sup>.  
19 Moreover, fewer prolonged sedentary bouts (i.e.  $\geq 30$  min) may provide additional health benefits, as  
20 mortality risk is higher among individuals with prolonged sitting characteristics compared to peers with ST  
21 accumulated from less prolonged sedentary bouts<sup>27</sup>. MVPA did not change after the ST reduction booster,  
22 which is in accordance with earlier research and highlights that ST and MVPA are distinct behaviours that  
23 require specific targeting strategies<sup>20,28</sup>. Nevertheless, a sedentary behaviour change program can be seen  
24 as the first step to improve cardiovascular health and increase physical activity and cardiorespiratory

1 fitness in CAD patients<sup>4</sup>, which can be followed by a program to gradually increase the volume and intensity  
2 of physical activity levels.

3 Transient improvements in sedentary behaviour and PA characteristics have been found after  
4 CR<sup>2,8</sup>, but most patients relapse to a more physically inactive lifestyle in subsequent months<sup>29</sup>. Additional  
5 support for lifestyle changes is currently not well-structured after CR graduation<sup>9</sup>, which complicates a  
6 sustainable transition to a physically active lifestyle. Indeed, no changes in ST or PA were observed during  
7 the ~2 years between CR completion and enrolment in the present study (**Supplementary Figure 2** and  
8 **Supplementary Figure 3**). Moreover, the participation rate to this study was 55%, which was aligned with  
9 a study examining the participation rate to a follow-up questionnaire after 3.5 year (42-62%)<sup>30</sup>. Some of  
10 the participants mentioned that they were not interested to participate as they considered their  
11 rehabilitation as finished. So, an active transition from CR to lifelong maintenance of a healthy lifestyle is  
12 essential, while barriers such as the motivation of patients, costs, time and travel burden should be  
13 minimized<sup>9</sup>.

14 Our booster program shows potential to bridge the gap in preventive cardiology between cardiac  
15 rehabilitation graduation and long-term healthy lifestyle adherence. The brief and remote nature of the  
16 program enhances its accessibility, feasibility and scalability during the maintenance phase of patients with  
17 CAD. Previous studies showed that follow-up prompts, i.e. brief contacts after a comprehensive  
18 intervention, are an effective method of maintaining behaviour change, including physical activity<sup>10,31</sup>. In  
19 addition, eHealth is considered as a promising strategy to maintain a healthy lifestyle among CR  
20 graduates<sup>32</sup>, as online behavioral interventions appear to outperform other delivery methods because  
21 they can be easily tailored to individual preferences and allow for frequent and timely feedback<sup>33</sup>. Our  
22 study showed that the eHealth approach was not feasible for all participants.

23 One participant dropped-out because of a language barrier that was more apparent when delivering the  
24 intervention completely remote and two others dropped-out because of the complexity of this

1 intervention when delivered at home. However, it should be mentioned that these two participants were  
2 the oldest patients of our cohort (82 and 87 years old). As 47% of the participants was 70+ years old it  
3 seemed that only a very high age was a limitation for study participation. Altogether, we show the high  
4 potential of a short, remote booster program to assist patients with a healthy lifestyle beyond CR-  
5 completion.

6

### 7 **Towards implementation**

8 Our booster program was effective, but some elements can be optimized to facilitate large-scale  
9 implementation. For example, participants had to return the activity tracker after the intervention period.  
10 Exploring (financial) possibilities to give participants an activity tracker that they can keep, could increase  
11 self-monitoring after the intervention period, which is an important aspect in preventing relapse to  
12 previous behaviors<sup>34</sup>. Secondly, the smartphone application can be used more extensively by incorporating  
13 educational videos, offering the possibility of shared-goal setting with a dyad, facilitating a supportive  
14 social environment<sup>35</sup>. Machine-learning techniques can be adopted to deliver just-in-time notifications,  
15 with the content or timing tailored to the individual participant's data (e.g. no reminders just after a  
16 predefined PA session or when they are asleep)<sup>36</sup>. The combination of eHealth with personal contact by  
17 telephone or emails seems superior to achieve behavioral change<sup>37</sup>, which is supported by recent evidence  
18 suggesting that self-monitoring of behaviour with automatic generated feedback alone is not sufficient to  
19 improve PA or ST levels in patients with cardiovascular disease<sup>38,39</sup>. Taken together, future research should  
20 investigate how (smartphone) applications, connected wearables and the balance between personal and  
21 automated feedback could improve feasibility, usability and effectiveness of the booster intervention –  
22 and particularly in the long-term and outside of the context of a trial.

23

24



## 1 **Strengths and limitations**

2 To the best of our knowledge, we are the first to examine the effectiveness of a booster behaviour  
3 intervention aiming to reduce sedentary behaviour in CR graduates. Nevertheless, some limitations should  
4 be addressed. First, selection bias could have occurred as included participants may be more inclined to  
5 behaviour change compared to participants who declined participation, possibly leading to an  
6 overestimation of the effects. However, we compared the historical ST and PA characteristics and found  
7 no differences between participants and non-participants (**Supplementary Table 3**). Secondly, we  
8 examined the effectiveness of the booster program in participants who were familiar with the wearable  
9 and smartphone application, due to previous participation in the SIT LESS RCT (**Supplementary Figure 1**)<sup>20</sup>.  
10 This could have increased the feasibility of the remote booster program. Additional manuals or instructions  
11 might be needed for naive users to perform this remote program in different settings. Thirdly, the small  
12 sample size may limit the generalizability and did not allow us to assess differences in specific subgroups,  
13 for example gender-specific effects or the influence of certain comorbidities. Finally, the current study  
14 assessed short-term effects of this remote intervention, hence, long-term behaviour change necessary for  
15 beneficial health effects remains to be investigated.

## 17 **CONCLUSIONS**

18 The 3-week remote booster program effectively reduces sedentary behaviour and the number of  
19 prolonged sedentary bouts, while increasing LIPA in patients with CAD who followed CR with a ST reduction  
20 program. These findings highlight the potential to improve activity behaviour in patients beyond  
21 completion of traditional CR programs. The accessible and feasible delivery method offers the opportunity  
22 to use a booster program to transition from supervised exercise training sessions as part of CR to lifelong  
23 maintenance of physical activity in the patient's living environment, empowering sustainable lifestyle  
24 changes.

## 1 **ACKNOWLEDGEMENTS**

2 We sincerely thank all participants of this randomized controlled trial. We also thank Thomas Smit  
3 (Appbakkers B.V., Zwolle, The Netherlands), Coen Lauwerijssen and Michel Sperling (2M Engineering,  
4 Valkenswaard, The Netherlands) for technical support regarding the RISE application, web-based  
5 dashboard and Activ8 sit activity tracker.

## 7 **FUNDING**

8 This study was supported by the Dutch Heart Foundation (senior E-Dekker grant #2017T051). We have no  
9 declaration to make regarding the role of the funding body in the design of the study, the collection,  
10 analysis, and interpretation of data, and in writing the manuscript. The views expressed are those of the  
11 authors and not necessarily those of the funder. EAB has received funding from the European Union's  
12 Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No  
13 [101064851].

## 15 **CONFLICT OF INTEREST**

16 All authors declare that they have no competing interests.

## 18 **AUTHOR'S CONTRIBUTIONS**

19 Concept and Design: SK, BvB, EB, DT and TE; Acquisition, analysis, or interpretation of Data: SK, BvB, MB,  
20 MP, FBO, MH, DT, EB and TE; Drafting of the manuscript: SK; Critical review of the manuscript: BvB, MB,

1 MP, FBO, MH, DT, EB and TE; Statistical analysis: SK, FBO, EB, and TE; obtained funding: TE; Supervision:  
2 EB, MH and TE; Patient enrolment: SK.

3

#### 4 REFERENCES

- 5 1. Wu Z, Huang Z, Wu Y, Huang S, Wang Y, Zhao H, *et al.* Sedentary time, metabolic abnormalities,  
6 and all-cause mortality after myocardial infarction: A mediation analysis. *Eur J Prev Cardiol* 2019;26:96-  
7 104. doi: 10.1177/2047487318804611
- 8 2. Bakker EA, van Bakel BMA, Aengevaeren WRM, Meindersma EP, Snoek JA, Waskowsky WM, *et al.*  
9 Sedentary behaviour in cardiovascular disease patients: Risk group identification and the impact of cardiac  
10 rehabilitation. *Int J Cardiol* 2021;326:194-201. doi: 10.1016/j.ijcard.2020.11.014
- 11 3. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, *et al.* Dose-  
12 response associations between accelerometry measured physical activity and sedentary time and all cause  
13 mortality: systematic review and harmonised meta-analysis. *BMJ* 2019;366:l4570. doi: 10.1136/bmj.l4570
- 14 4. Dunstan DW, Dogra S, Carter SE, Owen N. Sit less and move more for cardiovascular health:  
15 emerging insights and opportunities. *Nat Rev Cardiol* 2021. doi: 10.1038/s41569-021-00547-y
- 16 5. Matthews CE, Moore SC, Sampson J, Blair A, Xiao Q, Keadle SK, *et al.* Mortality Benefits for  
17 Replacing Sitting Time with Different Physical Activities. *Med Sci Sports Exerc* 2015;47:1833-1840. doi:  
18 10.1249/MSS.0000000000000621
- 19 6. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, *et al.* 2021 ESC Guidelines on  
20 cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular  
21 disease prevention in clinical practice with representatives of the European Society of Cardiology and 12  
22 medical societies With the special contribution of the European Association of Preventive Cardiology  
23 (EAPC). *Eur Heart J* 2021. doi: 10.1093/eurheartj/ehab484
- 24 7. Dibben GO, Dalal HM, Taylor RS, Doherty P, Tang LH, Hillsdon M. Cardiac rehabilitation and  
25 physical activity: systematic review and meta-analysis. *Heart* 2018;104:1394-1402. doi: 10.1136/heartjnl-  
26 2017-312832
- 27 8. Ter Hoeve N, Sunamura M, van Geffen ME, Fanchamps MH, Horemans HL, Busmann JB, *et al.*  
28 Changes in Physical Activity and Sedentary Behavior During Cardiac Rehabilitation. *Arch Phys Med Rehabil*  
29 2017;98:2378-2384. doi: 10.1016/j.apmr.2017.05.008
- 30 9. Heimer M, Schmitz S, Teschler M, Schäfer H, Douma ER, Habibovic M, *et al.* eHealth for  
31 maintenance cardiovascular rehabilitation: a systematic review and meta-analysis. *Eur J Prev Cardiol*  
32 2023;30:1634-1651. doi: 10.1093/eurjpc/zwad145
- 33 10. Fleig L, Pomp S, Schwarzer R, Lippke S. Promoting exercise maintenance: how interventions with  
34 booster sessions improve long-term rehabilitation outcomes. *Rehabil Psychol* 2013;58:323-333. doi:  
35 10.1037/a0033885
- 36 11. van Bakel BMA, Kroesen SH, Günal A, Scheepmaker A, Aengevaeren WRM, Willems FF, *et al.*  
37 Sedentary Behaviour Intervention as a Personalised Secondary Prevention Strategy (SIT LESS) for patients  
38 with coronary artery disease participating in cardiac rehabilitation: rationale and design of the SIT LESS  
39 randomised clinical trial. *BMJ Open Sport Exerc Med* 2022;8:e001364. doi: 10.1136/bmjsem-2022-001364
- 40 12. Schulz KF, Altman DG, Moher D, the CG. CONSORT 2010 Statement: updated guidelines for  
41 reporting parallel group randomised trials. *BMC Med.* 2010;8:18. doi: 10.1186/1741-7015-8-18

- 1 13. Kok G, Gottlieb NH, Peters GJ, Mullen PD, Parcel GS, Ruiter RA, *et al.* A taxonomy of behaviour  
2 change methods: an Intervention Mapping approach. *Health Psychol. Rev.* 2016;10:297-312. doi:  
3 10.1080/17437199.2015.1077155
- 4 14. van Bakel BMA, Kroesen SH, Bakker EA, van Miltenburg RV, Günal A, Scheepmaker A, *et al.*  
5 Effectiveness of an intervention to reduce sedentary behaviour as a personalised secondary prevention  
6 strategy for patients with coronary artery disease: main outcomes of the SIT LESS randomised clinical trial.  
7 *Int J Behav Nutr Phys Act* 2023;20:17. doi: 10.1186/s12966-023-01419-z
- 8 15. Fanchamps MHJ, Horemans HLD, Ribbers GM, Stam HJ, Bussmann JBJ. The Accuracy of the  
9 Detection of Body Postures and Movements Using a Physical Activity Monitor in People after a Stroke.  
10 *Sensors* 2018;18:2167. doi:  
11 16. Edwardson CL, Rowlands AV, Bunnewell S, Sanders J, Esliger DW, Gorely T, *et al.* Accuracy of  
12 Posture Allocation Algorithms for Thigh- and Waist-Worn Accelerometers. *Med Sci Sports Exerc*  
13 2016;48:1085-1090. doi: 10.1249/MSS.0000000000000865
- 14 17. Winkler EA, Bodicoat DH, Healy GN, Bakrania K, Yates T, Owen N, *et al.* Identifying adults' valid  
15 waking wear time by automated estimation in activPAL data collected with a 24 h wear protocol. *Physiol.*  
16 *Meas.* 2016;37:1653-1668. doi: 10.1088/0967-3334/37/10/1653
- 17 18. Tremblay MS, Aubert S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, *et al.* Sedentary  
18 Behavior Research Network (SBRN) - Terminology Consensus Project process and outcome. *Int J Behav*  
19 *Nutr Phys Act* 2017;14:75. doi: 10.1186/s12966-017-0525-8
- 20 19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic  
21 comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373-383. doi:  
22 10.1016/0021-9681(87)90171-8
- 23 20. Kroesen SH, van Bakel BMA, de Bruin M, Günal A, Scheepmaker A, Aengevaeren WRM, *et al.* A  
24 cardiac-rehab behaviour intervention to reduce sedentary time in coronary artery disease patients: the  
25 SIT LESS randomized controlled trial. *Int J Behav Nutr Phys Act* 2024;21:90. doi: 10.1186/s12966-024-  
26 01642-2
- 27 21. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power analysis program  
28 for the social, behavioral, and biomedical sciences. *Behav. Res. Methods* 2007;39:175-191. doi:  
29 10.3758/bf03193146
- 30 22. Coffman CJ, Edelman D, Woolson RF. To condition or not condition? Analysing 'change' in  
31 longitudinal randomised controlled trials. *BMJ Open* 2016;6:e013096. doi: 10.1136/bmjopen-2016-  
32 013096
- 33 23. Chastin SF, Palarea-Albaladejo J, Dontje ML, Skelton DA. Combined Effects of Time Spent in  
34 Physical Activity, Sedentary Behaviors and Sleep on Obesity and Cardio-Metabolic Health Markers: A Novel  
35 Compositional Data Analysis Approach. *PLoS One* 2015;10:e0139984. doi: 10.1371/journal.pone.0139984
- 36 24. Migueles JH, Cadenas-Sanchez C, Lubans DR, Henriksson P, Torres-Lopez LV, Rodriguez-Ayllon M,  
37 *et al.* Effects of an Exercise Program on Cardiometabolic and Mental Health in Children With Overweight  
38 or Obesity: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Netw Open* 2023;6:e2324839. doi:  
39 10.1001/jamanetworkopen.2023.24839
- 40 25. Stephenson A, McDonough SM, Murphy MH, Nugent CD, Mair JL. Using computer, mobile and  
41 wearable technology enhanced interventions to reduce sedentary behaviour: a systematic review and  
42 meta-analysis. *Int J Behav Nutr Phys Act* 2017;14:105. doi: 10.1186/s12966-017-0561-4
- 43 26. Blodgett JM, Ahmadi MN, Atkin AJ, Chastin S, Chan H-W, Suorsa K, *et al.* Device-measured physical  
44 activity and cardiometabolic health: the Prospective Physical Activity, Sitting, and Sleep (ProPASS)  
45 consortium. *Eur Heart J* 2023. doi: 10.1093/eurheartj/ehad717
- 46 27. Diaz KM, Howard VJ, Hutto B, Colabianchi N, Vena JE, Safford MM, *et al.* Patterns of Sedentary  
47 Behavior and Mortality in U.S. Middle-Aged and Older Adults: A National Cohort Study. *Ann Intern Med*  
48 2017;167:465-475. doi: 10.7326/m17-0212

- 1 28. Nieste I, Franssen WMA, Spaas J, Bruckers L, Savelberg H, Eijnde BO. Lifestyle interventions to  
2 reduce sedentary behaviour in clinical populations: A systematic review and meta-analysis of different  
3 strategies and effects on cardiometabolic health. *Prev Med* 2021;148:106593. doi:  
4 10.1016/j.ypmed.2021.106593
- 5 29. Hansen D, Dendale P, Raskin A, Schoonis A, Berger J, Vlassak I, Meeusen R. Long-term effect of  
6 rehabilitation in coronary artery disease patients: randomized clinical trial of the impact of exercise  
7 volume. *Clin. Rehabil.* 2010;24:319-327. doi: 10.1177/0269215509353262
- 8 30. Bauman A, Phongsavan P, Cowle A, Banks E, Jorm L, Rogers K, *et al.* Maximising follow-up  
9 participation rates in a large scale 45 and Up Study in Australia. *Emerg Themes Epidemiol* 2016;13:6. doi:  
10 10.1186/s12982-016-0046-y
- 11 31. Fjeldsoe B, Neuhaus M, Winkler E, Eakin E. Systematic review of maintenance of behavior change  
12 following physical activity and dietary interventions. *Health Psychol* 2011;30:99-109. doi:  
13 10.1037/a0021974
- 14 32. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, *et al.* 2023 ESC Guidelines for the  
15 management of acute coronary syndromes: Developed by the task force on the management of acute  
16 coronary syndromes of the European Society of Cardiology (ESC). *Eur Heart J* 2023;44:3720-3826. doi:  
17 10.1093/eurheartj/ehad191
- 18 33. Ma H, Wang A, Pei R, Piao M. Effects of habit formation interventions on physical activity habit  
19 strength: meta-analysis and meta-regression. *Int J Behav Nutr Phys Act* 2023;20:109. doi: 10.1186/s12966-  
20 023-01493-3
- 21 34. Kwasnicka D, Dombrowski SU, White M, Sniehotta F. Theoretical explanations for maintenance of  
22 behaviour change: a systematic review of behaviour theories. *Health Psychol. Rev.* 2016;10:277-296. doi:  
23 10.1080/17437199.2016.1151372
- 24 35. Carr RM, Prestwich A, Kwasnicka D, Thøgersen-Ntoumani C, Gucciardi DF, Quested E, *et al.* Dyadic  
25 interventions to promote physical activity and reduce sedentary behaviour: systematic review and meta-  
26 analysis. *Health Psychol. Rev.* 2019;13:91-109. doi: 10.1080/17437199.2018.1532312
- 27 36. Hardeman W, Houghton J, Lane K, Jones A, Naughton F. A systematic review of just-in-time  
28 adaptive interventions (JITAs) to promote physical activity. *Int J Behav Nutr Phys Act* 2019;16:31. doi:  
29 10.1186/s12966-019-0792-7
- 30 37. Fry JP, Neff RA. Periodic prompts and reminders in health promotion and health behavior  
31 interventions: systematic review. *J. Med. Internet Res.* 2009;11:e16. doi: 10.2196/jmir.1138
- 32 38. Patterson K, Davey R, Keegan R, Niyonsenga T, Mohanty I, Bowen S, *et al.* Testing the Effect of a  
33 Smartphone App on Hospital Admissions and Sedentary Behavior in Cardiac Rehabilitation Participants:  
34 ToDo-CR Randomized Controlled Trial. *JMIR Mhealth Uhealth* 2023;11:e48229. doi: 10.2196/48229
- 35 39. Golbus JR, Gupta K, Stevens R, Jeganathan VSE, Luff E, Shi J, *et al.* A randomized trial of a mobile  
36 health intervention to augment cardiac rehabilitation. *NPJ Digit Med* 2023;6:173. doi: 10.1038/s41746-  
37 023-00921-9

38

39 **FIGURE LEGENDS**

40 **Graphical Abstract.** \*Significant difference. CAD: Coronary artery disease; LIPA: Light intensity physical  
41 activity; MVPA: Moderate-to-vigorous physical activity; ST: Sedentary time.

1 **Figure 1. CONSORT flowchart of our randomized controlled trial.** Of the original SIT LESS cohort of 97  
2 participants, 87 (100%) were eligible for study participation. 48 (55%) were randomized to either the  
3 booster intervention (n=23) or control group (n=25) and the analytical cohort included 42 participants  
4 (48%, booster: n=21, control: n=21).

5  
6 **Figure 2. Constrained linear mixed model sedentary behaviour outcomes.** The total study cohort is  
7 depicted at baseline (n=41, black) and post-intervention (booster: n=19, blue; control: n=21, red). (A)  
8 Sedentary time per day. The dashed line represents the level of sedentary time associated with higher  
9 mortality (9.5 h/day)<sup>3</sup>. (B) Number of prolonged sedentary time bouts ( $\geq 30$  min) per day. Values are  
10 provided per day and described with the mean and 95% confidence interval.

11  
12 **Figure 3. Constrained linear mixed model physical activity outcomes.** The total study cohort is depicted  
13 at baseline (n=41, black) and post-intervention (booster: n=19, blue; control: n=21, red). (A) Time spent in  
14 light intensity physical activity (LIPA). (B) Time spent in moderate-to-vigorous intensity physical activity  
15 (MVPA). (C) Number of steps. Values are provided per day and described with the mean and 95%  
16 confidence interval.

17  
18 **Figure 4. Change in daily activity composition for the booster and control group.** The change in daily  
19 activity composition was calculated as a percentage difference in compositional mean post-intervention  
20 compared to the baseline composition. Difference in composition change between booster (n=19) and  
21 control group (n=20) was assessed by the Hotelling's  $T^2$  test.

1 TABLES

2 Table 1. Baseline characteristics of the total study sample.

	Total study sample (n=42)	Booster intervention (n=21)	Control group (n=21)
<b>Age (years)</b>	69 [63-75]	69 [62-72]	69 [63-75]
<b>Gender (female)</b>	8 (19%)	3 (14%)	5 (24%)
<b>Body mass index (kg/m<sup>2</sup>)</b>	26.3 [23.8-27.9]	26.5 [23.3-27.4]	26.3 [24.9-28.1]
<b>Regular step count tracking by smartwatch or smartphone (n (%))</b>	18 (42%)	9 (42%)	9 (42%)
<b>Employed*</b>	22 (52%)	11 (52%)	11 (52%)
<b>Alcohol use (n (%))</b>	34 (81%)	15 (71%)	19 (90%)
Current drinker (n (%))	29 (85%)	13 (87%)	16 (84%)
Units/week (n)	3 [2-6]	4 [2-5]	2 [2-7]
<b>Smoking (n (%))</b>	23 (55%)	10 (48%)	13 (62%)
Current smoker (n (%))	2 (8%)	2 (20%)	0 (0%)
Packyears (n)	16 [5-24]	21 [12-24]	12 [5-20]
<b>Comorbidities</b>			
<b>Primary CAD diagnosis*</b>			
NSTEMI	24 (57%)	10 (48%)	14 (67%)
STEMI	10 (24%)	6 (28%)	4 (19%)
AP	8 (19%)	5 (24%)	3 (14%)
UAP	0 (0%)	0 (0%)	0 (0%)
<b>Charlson Comorbidity Index (% estimated 10-year survival)</b>	53 [21-89]	53 [21-77]	53 [2-90]
Hypertension (n (%))	19 (45%)	9 (43%)	10 (48%)
Dyslipidaemia (n (%))	9 (21%)	4 (19%)	5 (24%)
Diabetes mellitus (n (%))	4 (10%)	2 (10%)	2 (10%)
Prior myocardial infarction (n (%))	35 (83%)	16 (76%)	19 (90%)
Prior PCI (n (%))	26 (62%)	13 (62%)	13 (62%)
Prior CABG (n (%))	15 (36%)	6 (29%)	9 (43%)
Atrial fibrillation (n (%))	7 (17%)	4 (19%)	3 (14%)
Heart failure (n (%))	6 (14%)	1 (5%)	5 (24%)
Peripheral artery disease (n (%))	2 (5%)	0 (0%)	2 (10%)
Heart valve disease (n (%))	8 (19%)	3 (14%)	5 (24%)
Depression (n (%))	3 (7%)	0 (0%)	3 (14%)
Cancer (diagnosed in the past 5 years) (n (%))	5 (12%)	3 (14%)	2 (10%)
Rheumatoid arthritis (n (%))	0 (0%)	0 (0%)	0 (0%)
COPD (n (%))	1 (2%)	1 (5%)	0 (0%)
CVA (n (%))	2 (5%)	1 (5%)	1 (5%)
TIA (n (%))	1 (2%)	0 (0%)	1 (5%)
Chronic renal failure (eGFR<30 ml/min/1.73m <sup>2</sup> or dialysis) (n (%))	1 (5%)	0 (0%)	1 (5%)
<b>Cardiovascular medication</b>			

ACE-inhibitor/Angiotensin receptor blocker	26 (62%)	14 (67%)	12 (57%)
Anticoagulant	3 (7%)	2 (10%)	1 (5%)
Beta-blocker	20 (48%)	10 (48%)	10 (48%)
PCSK9 inhibitor	0 (0%)	0 (0%)	0 (0%)
Platelet aggregation inhibitor	35 (83%)	19 (91%)	16 (76%)
Statins	37 (88%)	20 (95%)	17 (81%)

1 Data are presented as n (%) for categorical variables and as mean ( $\pm$  standard deviation) or median [interquartile  
2 range] for continuous variables. There were no missing data. ACE: Angiotensin-converting enzyme; AP: angina  
3 pectoris; CABG: coronary artery bypass grafting; COPD: chronic obstructive pulmonary disease; CVA:  
4 cerebrovascular accident; NSTEMI: non-ST-elevated myocardial infarction; PCI: Percutaneous Coronary  
5 Intervention; PCSK9: proprotein convertase subtilisin-kexin type 9; STEMI: ST-elevated myocardial infarction;  
6 TIA: Transient ischemic attack; UAP: unstable angina pectoris \*Data collected during the SIT LESS study.






Figure 1  
229x331 mm (x DPI)

1  
2  
3  
4




Figure 2  
 237x161 mm (x DPI)

1  
 2  
 3





Figure 3  
264x120 mm (x DPI)

1  
2  
3


ACCEPTED MANUSCRIPT



1  
2  
3  
4

Figure 4  
297x210 mm (x DPI)

## Effectiveness of a 3-week remote booster intervention on sedentary time changes in patients with coronary artery disease



1  
2  
3

Graphical Abstract  
180x125 mm (x DPI)